As Pear Therapeutics’ financial situation forces the company into bankruptcy, Ben Hargreaves takes a look at whether this is just a blip on the road for digital therapeutics, or a sign of darker ...
Pear Therapeutics received market authorization from the FDA for its insomnia digital therapeutic, Somryst. It is Pear’s third product to receive FDA clearance, and the first product to be ...
PEAR Therapeutics has raised $50m in a new financing round to fund development of its prescription digital therapeutics business. Prescription digital therapeutics are clinically-validated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback